Viyash ScientificQ1 FY27
Viyash Scientific Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹278P/E: 54.8Market Cap: ₹12.1K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- →Expect steady double-digit revenue growth with 15%-17% growth in next 2 years (up to 2028) before acceleration.
- →Significant growth anticipated post-2029, driven by patent expiries on Animal Health (2027-2033) and Human API products (post-2030).
- →Majority of new product revenues expected from 2029 onwards, considering 3-5 years gestation for product development and regulatory approvals.
- →Animal Health segment growing faster, currently about one-third of API revenue, with focus on formulations and expanding manufacturing capacity.
- →European acquisition (BioForLife) to contribute substantially after 2-3 years (post-2028) with estimated €150-200 million revenue by 2032.
- →Emerging markets (Turkey, Brazil, Mexico) showing strong volume growth (~25%), expected to sustain momentum.
- →Human API portfolio targets 10%-15% market share per product, focusing on first-to-file launches and sustainability.
- →Overall, confident in achieving an 18% CAGR up to 2032, with balanced organic and inorganic growth strategies.
Margin guidance
Category 3- →Company expects sustainable double-digit revenue growth, targeting around 15%-17% growth over the next 2 years.
- →Majority of new product revenue is expected from 2029 onwards due to product gestation and patent expiries.
- →The 2032 aspiration includes reaching revenues of $150-200 million in companion animal segment, supported by organic growth and inorganic acquisitions.
- →EBITDA margins targeted around 20%-22%, with continuous margin expansion expected.
- →Profit after tax doubled year-on-year in Q1 FY’27, indicating strong profitability momentum.
- →API and Animal Health segments to grow mid-teens to 20%+ over near term.
- →Acquisition synergy and market expansion in Europe to contribute to growth from 2029 onwards.
- →CAPEX planned in range of Rs. 250-300 crores to support manufacturing capacity and R&D.
- →Overall, confident of an 18% CAGR revenue growth towards FY2032 with improving profitability and EPS.
3 more insights locked — sign up free to unlock
Fundraise plans
Yes- →There is no explicit mention of any immediate or planned new fundraising through debt or equity in the provided transcript.
- →The company has significantly reduced its net debt to Rs. 86 crores with a net debt-to-EBITDA ratio of 0.1x, indicating a virtually debt-free status on a net basis.
- →Management highlighted a strong balance sheet that provides flexibility for brownfield expansion and inorganic growth through acquisitions.
- →They emphasized disciplined capital allocation with a CAPEX guidance of Rs. 250-300 crores annually, which is manageable given the company size.
- →Considering the strong balance sheet, they expect to fund growth organically or through selective inorganic deals without immediate new major fundraising.
- →They continuously evaluate opportunities for acquisitions and minority interest buybacks over the next 1-2 years with possible use of existing financial strength rather than fresh funding.
Order book
The transcript does not explicitly mention the current or expected order book or pending orders in specific terms. However, relevant insights include:
- Post-acquisition of BioForLife (Italy), registrations and marketing are expected to take 18-24 months before significant revenue impact.
- Product launches and R&D investments for companion animals are ramping up, with manufacturing readiness expected by January 2027.
- A strong product pipeline in emerging markets (Turkey, Brazil, Mexico) and Europe supports growth.
- API business faced some quarter-on-quarter timing delays due to raw material volatility but expects a strong quarter with many orders returning.
- First-to-file opportunities and new product registrations imply a pipeline geared towards growth starting mainly from 2029 onwards.
- Overall, growth visibility and order intake appear robust, supported by ongoing product launches, geographic expansion, and acquisitions.
Capex plans
Yes- →Capex guidance for FY’27 is around Rs. 250 crores to Rs. 300 crores.
- →Current capital allocation is balanced; majority business (90%) is mature and requires limited new investment.
- →New investments focus on R&D, manufacturing expansion, and strategic areas like high potent API and formulation capabilities.
- →Manufacturing plant for companion animal products being prepared with expected readiness by January-February following equipment orders placed and design finalization.
- →Company plans selective inorganic growth via acquisitions aligned with strategic direction (Animal Health, CDMO, complex molecules).
- →Interest cost restructuring underway to optimize financing costs.
- →M&A activity expected to accelerate growth; minority interests in US and Spain anticipated to be acquired within next 1-2 years.
- →Overall, capital allocation is disciplined with focus on compliance, sustainable growth, and integrating new capabilities.
How does Viyash Scientific rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Viyash Scientific
Rev 3Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
How does Viyash Scientific rank in Pharmaceuticals & Biotechnology?
Compare Viyash Scientific against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.